Few areas of metabolic science have moved as quickly over the past decade as increasing research. What began as the study of a single gut hormone has grown into a family of engineered peptides that act on one, two, or even three metabolic receptors at once. For laboratories working in this space, understanding how these compounds differ — in structure, in mechanism, and in what the published literature actually shows — is the starting point for sound experimental design.
This guide walks through the major incretin-related peptide classes, explains where GLP-3 fits among them, and outlines what researchers should weigh when choosing a compound for in-vitro work.
All compounds discussed here are research chemicals. Nothing in this article is medical advice, and none of the materials described are intended for human or veterinary use.
What Are Incretins?
Incretins are hormones released by the gut after a meal that amplify insulin secretion in a glucose-dependent way. Two have been studied most closely:
- GLP-1 (glucagon-like peptide-1) is produced by L-cells in the small intestine and colon. It stimulates insulin release, suppresses glucagon, slows gastric emptying, and acts on appetite centers in the brain.
- GIP (glucose-dependent insulinotropic polypeptide) is produced by K-cells in the upper small intestine. It also enhances insulin secretion and appears to play a role in fat metabolism and energy storage.
Native GLP-1 and GIP are broken down by the enzyme DPP-4 within minutes, which makes them impractical to study over longer timeframes. That limitation drove the development of stabilized analogues — and, eventually, multi-receptor agonists.
A third hormone, glucagon, is not an incretin, but it belongs to the same peptide family and shares close structural similarity. Its receptor has become an important research target because glucagon signaling increases energy expenditure and influences how the liver handles fat.
Generation One: Single-Receptor GLP-1 Agonists
The first wave of incretin-based compounds targeted the GLP-1 receptor alone. Exenatide, derived from a peptide found in Gila monster saliva, was followed by liraglutide and then semaglutide, each engineered for greater resistance to enzymatic breakdown and a longer half-life.
In research settings, single-agonist GLP-1 compounds remain valuable reference tools. Their mechanism is well characterized, which makes them a reliable baseline when comparing newer multi-receptor molecules. Their limitation, from a research standpoint, is scope: they engage only one pathway, so on their own they reveal little about how combined receptor signaling shapes metabolic outcomes.
Generation Two: Dual Agonists
The next step was to build a single molecule that activates two receptors at once.
GIP/GLP-1 dual agonists. Tirzepatide is the best-known example. Published clinical data showed stronger effects on glycemic markers and body weight than GLP-1 agonism alone, suggesting the two pathways work in a complementary way rather than simply overlapping.
GLP-1/glucagon dual agonists. A parallel line of research paired GLP-1 with glucagon receptor activity. Compounds such as survodutide and mazdutide were designed to combine GLP-1’s effects on insulin and appetite with glucagon’s influence on energy expenditure and hepatic fat. These molecules have drawn particular interest in liver-focused metabolic research.
Dual agonists opened a central research question: when receptors are activated together, is the result simply additive, or do the pathways interact in ways neither produces alone? That question led directly to the third generation.
Where GLP-3 Fits: The Triple-Agonist Approach
In the research peptide field, “GLP-3” is the name commonly used for triple-agonist compounds that act on the GIP, GLP-1, and glucagon receptors simultaneously. The most widely studied molecule in this class is retatrutide (LY3437943).
It is worth being precise here: “GLP-3” is a shorthand label, not the name of a naturally occurring hormone. There is no endogenous “glucagon-like peptide-3” — the number refers to the three receptor targets the molecule engages.
The rationale behind triple agonism is to combine three complementary mechanisms in one sequence:
- GLP-1 activity for glucose-dependent insulin secretion and appetite regulation
- GIP activity for additional insulin effects and lipid handling
- Glucagon activity for increased energy expenditure and liver fat oxidation
In a phase 2 trial published in the New England Journal of Medicine in 2023, retatrutide produced mean body-weight reductions of roughly 24% at 48 weeks in the highest-dose group — the largest effect reported for this class of peptide at the time. Larger phase 3 programs have since been underway to gather longer-term data.
For laboratories, the appeal of GLP-3 is straightforward: it allows three interacting hormonal pathways to be studied within a single, stable molecule, rather than approximating that effect with combinations of separate compounds.
Side-by-Side Comparison
| GLP-1 Agonists | GIP/GLP-1 Dual | GLP-1/Glucagon Dual | GLP-3 (Triple) | |
| Receptors | GLP-1 | GIP + GLP-1 | GLP-1 + Glucagon | GIP + GLP-1 + Glucagon |
| Example compounds | Semaglutide, liraglutide | Tirzepatide | Survodutide, mazdutide | Retatrutide |
| Primary research focus | Glucose control, appetite signaling | Combined insulin and lipid effects | Energy expenditure, liver fat | Multi-pathway metabolic regulation |
| Research maturity | Most extensively characterized | Well characterized | Growing body of data | Newest; highly active area |
Key Considerations When Choosing a Research Peptide
1. Match the compound to the research question. If you are isolating a single pathway, a GLP-1 agonist may be the cleaner tool. If you want to study receptor interplay, a dual or triple agonist makes more sense. Running several classes side by side lets you separate each receptor’s contribution to an observed effect.
2. Verify purity and identity. Multi-receptor peptides are long, complex sequences, and small synthesis errors or impurities can alter receptor binding and skew results. Look for lot-specific HPLC purity data and mass spectrometry confirmation. You can read more about how we verify every batch on our About page.
3. Handle and store correctly. Lyophilized peptides should be kept frozen at -20°C for long-term stability. Once reconstituted, store at 2–8°C and use within the experimental timeline to limit degradation.
4. Account for the literature gap. Single agonists have a long publication history. Triple agonists are newer, and much of the available data comes from a relatively small number of sponsor-run studies. Design your controls and interpret results with that in mind.
Why the Triple-Agonist Class Matters
The move from single to triple agonists reflects a broader shift in how metabolic science views energy balance: not as a one-hormone system, but as a network in which gut, pancreatic, and liver signals continuously adjust one another. Triple agonists give researchers a way to probe that network directly.
Important questions remain open — how the relative potency at each receptor shapes outcomes, how signaling balance changes over time, and how these compounds affect tissues beyond the pancreas and liver. These are exactly the kinds of questions well-controlled laboratory research is positioned to answer.
Conclusion
Incretin research has evolved from single-hormone analogues to engineered molecules that engage multiple metabolic receptors at once. GLP-1 agonists remain the best-characterized reference point. Dual agonists showed that combined signaling can outperform a single pathway. GLP-3 triple agonists now extend that idea further by adding glucagon receptor activity to the mix.
For laboratories exploring this frontier, compound quality matters as much as compound choice. Browse our verified research peptide catalog to review lot-tested materials, or contact our team with questions about COAs, storage, or availability for your institution.